NDC 17856-0353-2 - Pharbetol Regular strength
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 17856-0353
- Requested NDC
- 17856-0353-2
- Package NDCs from labels
- 17856-0353-2, 17856-0353-1, 17856-0353-4, 17856-0353-3
- Manufacturer
- ATLANTIC BIOLOGICALS CORP.
- Effective date
- 2025-06-05
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| PHARBEST IBUPROFEN Drug Facts | ATLANTIC BIOLOGICALS CORP. | 2025-06-05 | HUMAN OTC DRUG LABEL |
| Pharbetol Regular strength - ATLANTIC BIOLOGICALS CORP. | UNIT DOSE SOLUTIONS | ATLANTIC BIOLOGICALS CORP. | UNIT DOSE SOLUTIONS | 2024-04-30 | HUMAN OTC DRUG LABEL |
FDA-Initiated Inactive NDC Indexing#
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 17856-0353-1 | 2024-06-26 | C162847 | 48780-1 | 1030e365-250f-111a-e063-dadaa90a10e2 | PHARBEST IBUPROFEN Drug Facts |
| 17856-0353-1 | 2024-01-30 | C162847 | 48780-1 | 1030e365-250f-111a-e063-dadaa90a10e2 | PHARBEST IBUPROFEN Drug Facts |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 17856-0353-1 | PharbetolRegular strength | 100 in 1 BOX, UNIT-DOSE | TABLET | 100 | 3 | |
| 17856-0353-2 | PharbetolRegular strength | 1 in 1 POUCH | TABLET | 1 | 3 | |
| 17856-0353-4 | PharbetolRegular strength | 24 in 1 BOTTLE | TABLET | 24 | 3 | |
| 17856-0353-3 | PharbetolRegular strength | 28 in 1 BOTTLE | TABLET | 28 | 1 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 17856-0353 | PHARBETOL REGULAR STRENGTH (ACETAMINOPHEN) TABLET [ATLANTIC BIOLOGICALS CORP.] | 2 | Current NDC, Legacy NDC, 3 package rows | 20240627_05a91d24-b498-4ba2-a275-68b871cf62d2.zip |
| 17856-0353 | PHARBETOL REGULAR STRENGTH (ACETAMINOPHEN) TABLET [ATLANTIC BIOLOGICALS CORP.] | 1 | Current NDC, Legacy NDC, 1 package rows | 20240508_bd26081c-e81e-42e8-b3da-2813863a51df.zip |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Sinus Pressure plus Pain PE | ACETAMINOPHEN AND PHENYLEPHRINE HYDROCHLORIDE | MARC GLASSMAN, INC. | a8240d98-f0b0-3ded-e053-2a95a90a5cf9 | 2024-10-23 | Warnings | 362O9ITL9D |
| Sinus plus Headache | ACETAMINOPHEN AND PHENYLEPHRINE HYDROCHLORIDE | MARC GLASSMAN, INC. | a82401f5-65b1-11e9-e053-2a95a90a499e | 2024-10-23 | Warnings | 362O9ITL9D |
| Allergy Multi Symptom | ACETAMINOPHEN, CHLORPHENIRAMINE MALEATE, AND PHENYLEPHRINE HYDROCHLORIDE | MARC GLASSMAN, INC. | a823db21-4863-45a6-e053-2995a90ab8e6 | 2024-10-23 | Warnings | 362O9ITL9D |
| Cold Max | ACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE, AND PHENYLEPHRINE HYDROCHLORIDE | MARC GLASSMAN, INC. | e2346d0c-75cf-974c-e053-2a95a90a2857 | 2024-10-23 | Warnings | 362O9ITL9D |
| Cold Multi-Symptom Nighttime | ACETAMINOPHEN, CHLORPHENIRAMINE MALEATE, DEXTROMETHORPHAN HYDROBROMIDE, AND PHENYLEPHRINE HYDROCHLORIDE | Marc Glassman, Inc. | ce573785-f77d-4314-9b7a-ef3f1f4f34d8 | 2024-10-23 | Warnings | 362O9ITL9D |
| Cold plus Flu Severe | ACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE | MARC GLASSMAN, INC. | e41a3dcc-45b4-4093-e053-2995a90a3b14 | 2024-10-23 | Warnings | 362O9ITL9D |
| Pain Relief Extra Strength | ACETAMINOPHEN | MARC GLASSMAN, INC. | e23703bb-6087-7985-e053-2995a90aa5ec | 2024-10-23 | Warnings | M013 362O9ITL9D |
| Pain Relief PM Extra Strength | ACETAMINOPHEN AND DIPHENHYDRAMINE HYDROCHLORIDE | MARC GLASSMAN, INC. | e237550d-711d-5d87-e053-2995a90affce | 2024-10-23 | Warnings | M013 362O9ITL9D |
| Cold plus Head Congestion Severe | ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE | MARC GLASSMAN, INC. | e41a7cc5-bd0e-b92b-e053-2995a90af50a | 2024-10-23 | Warnings | 362O9ITL9D |
| Nighttime | ACETAMINOPHEN, DEXTROMETHORPHAN HBR, DOXYLAMINE SUCCINATE | Kroger Company | 1cd26a6a-4b50-4610-9fc8-278545d77f18 | 2024-10-23 | Warnings | 362O9ITL9D |
| Nighttime Cold and Flu Relief | ACETAMINOPHEN, DEXTROMETHORPHAN HBR, DOXYLAMINE SUCCINATE | CVS Pharmacy | c5dd40e5-b4e2-4963-9a53-b71da1ed5510 | 2024-10-23 | Warnings | 362O9ITL9D |
| Aspirin | ASPIRIN | HARRIS TEETER | a6f15f71-1327-4b71-b9d6-e3e9f0243801 | 2024-10-22 | Warnings | M013 |
| Sinus plus Headache | ACETAMINOPHEN AND PHENYLEPHRINE HYDROCHLORIDE | Harris Teeter | c9d82968-b2ec-2f4b-e053-2a95a90a7f0c | 2024-10-22 | Warnings | 362O9ITL9D |
| Cold Max | ACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE, AND PHENYLEPHRINE HYDROCHLORIDE | Harris Teeter | b9d9ab99-44b1-455f-a29a-95c193a4808e | 2024-10-22 | Warnings | 362O9ITL9D |
| Mucus Relief Sinus Severe Congestion and Pain | ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE | HARRIS TEETER | b96c376e-578f-1124-e053-2a95a90acbb4 | 2024-10-22 | Warnings | 362O9ITL9D |
| Cold Head Congestion Severe | ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE | Harris Teeter | c92b508b-e5f9-4149-8c4b-d21845943b3b | 2024-10-22 | Warnings | 362O9ITL9D |
| Pain Relief Regular Strength | ACETAMINOPHEN | MARC GLASSMAN, INC. | e21e821c-9694-5db0-e053-2995a90ad034 | 2024-10-22 | Warnings | M013 313782 362O9ITL9D |
| Pain Relief Extra Strength | ACETAMINOPHEN | MARC GLASSMAN, INC. | e21e90e8-b9f1-1133-e053-2995a90a664b | 2024-10-22 | Warnings | M013 362O9ITL9D |
| aspirin | ASPIRIN | Publix Super Markets Inc | c51dae48-aa49-4926-b04a-0da264e08dfa | 2024-10-22 | Warnings | M013 |
| Acetaminophen Extra Strength | ACETAMINOPHEN | KROGER COMPANY | b96a2280-ec4f-7c61-e053-2995a90a18bb | 2024-10-22 | Warnings | M013 362O9ITL9D |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.